# Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment

> **NCT03052517** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 2538 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** QAW039 150 mg
- **DRUG:** QAW039 450 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03052517
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-21
- **Primary completion:** 2020-02-19
- **Final completion:** 2020-03-16
- **Target enrollment:** 2538 (ACTUAL)
- **Why stopped:** Company Decision
- **Last updated:** 2020-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03052517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03052517, "Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT03052517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*